After further adjusting for lipid-lowering drugs use in Model 3, the prevalence of T2D in the second and third quartiles of ApoA1 decreased 85% (OR = 0.15, 95% CI: 0.07, 0.34) and 63% (OR = 0.37, 95% CI: 0.20, 0.68) compared to the first quartile, respectively. The gene discussed is APOA1; the disease is type 2 diabetes mellitus.